Preclinical study demonstrates that mTORC1 inhibition rescues differentiation capacity in progeroid muscle stem cells, suggesting a therapeutic strategy to improve tissue regeneration during aging.
MDSPCs. Our results demonstrate that age-related adult stem/progenitor cell dysfunction contributes to impaired regenerative capacities and that mTORC1 inhibition may represent a potential therapeutic strategy for improving differentiation capacities of senescent stem and muscle progenitor cells.
No takes yet. Share an insight, caveat, or question.
Kawakami et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: